NEW YORK (GenomeWeb News) – Cepheid reported after the close of the market Thursday that its third-quarter revenues increased 15 percent and were in line with a pre-announcement the firm made regarding the quarter late last month.

The Sunnyvale, Calif.-based molecular diagnostics firm reported total revenues of $80.5 million for the three months ended Sept. 30, up from $70.2 million for the third quarter of 2011. Wall Street analysts, on average, expected revenues of $81 million.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

In a statement, National Institutes of Health Director Francis Collins says sexual harassment is "morally indefensible" and "unacceptable."

Stat News and ProPublica report that African Americans are underrepresented in cancer clinical trials.

Octopuses might owe their intelligence to their liberal alterations to their genes, Cosmos reports.

In Cell this week: genomic analysis of abdominal aortic aneurysm, effect of probiotics on the microbiome, and more.

Oct
02
Sponsored by
Roche

In the last few years several molecular testing methodologies — such as immunohistochemistry, PCR, and sequencing — have been approved by the US Food and Drug Administration to aid in the management of patients with lung cancer.  

Oct
10
Sponsored by
Philips Genomics

This webinar will provide a first-hand look at how the Dana-Farber Cancer Center is adapting its oncology care strategy in light of the rapidly evolving molecular landscape.